Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2012 Aug;32(8):3211-8.

Establishment and characterization of a new human gallbladder carcinoma cell line.

Author information

1
Department of Surgery and Science, University of Toyama, 2630 Sugitani, Toyama-city, Toyama, 930-0194, Japan. sekky@med.u-toyama.ac.jp

Abstract

BACKGROUND:

Prognosis for patients with gallbladder carcinoma (GBC) is poor and the standard treatment for GBC has not yet been established.

MATERIALS AND METHODS:

We established the human GBC cell line TYGBK-1, from a patient with papillary, tubular adenocarcinoma.

RESULTS:

The doubling time was 48 hours. This cell line has a missense mutation of p53 and no mutation of the K-RAS gene. This cell line was transplantable to nude mice. We characterized the sensitivity of TYGBK-1 to gemcitabine. We also examined the association of two gemcitabine-related genes (deoxycytidine kinase, dCK, and Hu antigen R, HuR). Among four GBC cell lines (TYGBK-1, NOZ, G-415, TGBC2TKB), TYGBK-1 and NOZ exhibited sensitivity to gemcitabine. Furthermore, these cells expressed both dCK and HuR mRNA, rather than gemcitabine-resistant cells.

CONCLUSION:

The newly established GBC cell line TYGBK-1, may represent an effective tool for development of chemotherapeutic treatment for GBC.

PMID:
22843894
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center